InterCure Ltd. (NASDAQ:INCR - Get Free Report) was the target of a large increase in short interest in May. As of May 15th, there was short interest totalling 13,000 shares, an increase of 21.5% from the April 30th total of 10,700 shares. Based on an average daily trading volume, of 14,900 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.1% of the shares of the stock are sold short.
Institutional Investors Weigh In On InterCure
An institutional investor recently bought a new position in InterCure stock. Moore Capital Management LP purchased a new position in InterCure Ltd. (NASDAQ:INCR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 97,273 shares of the company's stock, valued at approximately $156,000. Moore Capital Management LP owned approximately 0.21% of InterCure at the end of the most recent reporting period. 8.34% of the stock is currently owned by hedge funds and other institutional investors.
InterCure Price Performance
INCR stock traded down $0.05 during trading on Thursday, hitting $1.47. The company had a trading volume of 9,935 shares, compared to its average volume of 27,535. The company has a fifty day moving average price of $1.46 and a two-hundred day moving average price of $1.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.78 and a quick ratio of 1.15. InterCure has a fifty-two week low of $1.17 and a fifty-two week high of $2.62.
InterCure Company Profile
(
Get Free Report)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Read More
Before you consider InterCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InterCure wasn't on the list.
While InterCure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
